J. Matthews

发表

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

C. D’Este, D. Joseph, N. Spry, 2011, The Lancet. Oncology.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

B. Delahunt, P. McElduff, D. Joseph, 2012, The Lancet. Oncology.

Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer.

B. Delahunt, P. McElduff, D. Joseph, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.

B. Delahunt, C. Oldmeadow, J. Attia, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

B. Leber, E. Eisenhauer, M. Minden, 2010, Leukemia & lymphoma.

Multi‐observer contouring of male pelvic anatomy: Highly variable agreement across conventional and emerging structures of interest

L. Holloway, P. Greer, R. Rai, 2019, Journal of medical imaging and radiation oncology.

Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers' experience

L. Stitt, Rasna Gupta, J. Matthews, 2015 .

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

B. Delahunt, C. Oldmeadow, J. Attia, 2019, The Lancet. Oncology.

Active surveillance guidance for New Zealand men with low-risk prostate cancer.

B. Delahunt, J. Matthews, J. Nacey, 2015, The New Zealand medical journal.

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.

P. Greer, C. D’Este, D. Joseph, 2009, International journal of radiation oncology, biology, physics.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.

P. Greer, C. D’Este, D. Joseph, 2008, The Lancet. Oncology.

Peripheral blood lymphocyte surface antigen expression and prognosis in myeloma: Australian Leukaemia Study Group Study.

J. Matthews, W. Sheridan, D. Joshua, 1994, Leukemia & lymphoma.

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer.

D. Joseph, N. Spry, J. Denham, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Squamous cell carcinoma of the lip: a retrospective review of the Peter MacCallum Cancer Institute experience 1979-88.

J. Matthews, J. Beresford, J. Ainslie, 2000, The Australian and New Zealand journal of surgery.

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

C. D’Este, D. Joseph, H. Mameghan, 2005, The Lancet. Oncology.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

B. Delahunt, C. Oldmeadow, J. Attia, 2014, The Lancet. Oncology.

What Is a Randomized Controlled Trial

J. Matthews, 2006 .

Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis.

D. Dunger, M. Cole, R. Wood, 2020, European journal of endocrinology.

Radiomics and radiogenomics in gliomas: a contemporary update

S. Manjila, P. Prasanna, N. Beig, 2021, British Journal of Cancer.

Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy

A. Gnanasakthy, M. Manfredi, G. Avanzini, 1992, The Italian Journal of Neurological Sciences.

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial

R. Fisher, H. Woo, M. Frydenberg, 2014, BJU international.

Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.

J. Matthews, J. Matthews, E. Benson, 1994, Blood.

Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer

B. Delahunt, P. Moscato, P. McElduff, 2014, BJU international.

Another form of subgroup to beware.

C. D’Este, D. Joseph, N. Spry, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.

C. D’Este, D. Joseph, H. Mameghan, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

D. Joseph, H. Mameghan, N. Spry, 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?

C. D’Este, D. Joseph, N. Spry, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

496 oral IMPORTANT MORTALITY REDUCTIONS BY SHORT TERM ANDROGEN DEPRIVATION AND RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER: 10 YEAR TRIAL DATA FROM TROG 96.01

C. D’Este, D. Joseph, N. Spry, 2011 .

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial

D. Joseph, N. Spry, J. Denham, 2012, Prostate cancer.